Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2000-06-21
2002-10-08
Aulakh, C. S. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S280400, C546S324000, C514S354000, C514S356000
Reexamination Certificate
active
06462057
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to a new class of compounds of pyridinium series and to their use in treatment of diabetes and related illnesses. More particularly the invention relates to compounds of this series, methods for their preparation, pharmaceutical composition containing these compounds and their use in the treatment of complications of diabetes mellitus. The compounds of this series exhibit AGE breaking activity, which is essential for the treatment of diabetic and aging-related complications including kidney disease, nerve damage, atherosclerosis, retinopathy and dermatological conditions. The invention also extends to the method of reversing the discoloration of teeth resulting from nonenzymatic browning in the oral cavity which comprises administration of an amount effective to reverse pre-formed advanced glycosylation crosslinks.
2. Description of the Prior Art
Maillard in 1912 found that reducing sugars, such as glucose and ribose react with proteins to form brown pigments. Further studies have shown that this is an irreversible non-enzymatic reaction, which occurs in several natural systems including stored foodstuff. Maillard reaction occurs in two stages, early and advanced. Initially, proteins react with glucose to form stable Amadori products, which subsequently cross-links to form advanced glycation end products (AGE). In most cases, the formation of AGE also accompanies browning of the proteins and increase in the fluorescence.
In diabetes, where blood glucose level is significantly higher than normal, the reaction of glucose with several proteins such as haemoglobin, lens crystallin and collagen, gives rise to the formation of AGE, which in turn, is responsible for the complications associated with diabetes, such as nephropathy, microangiopathy, endothelial dysfunction and other organ dysfunctions. In addition, the activity of several growth factors, such as basic fibroblast growth factor, is also impaired. AGE products, unlike normal proteins in tissue, have a slower rate of turnover and replenishment. It has been reported that AGE is products may in fact elicit a complex immunological reaction involving RAGE (Receptor for Advanced Glycation End Products) receptors and activation of several incompletely defined immunological processes. It has been documented that diabetes with evidence of microangiopathy and macroangiopathy also show evidence of oxidative stress, the mechanism of which has not been elucidated.
In vitro AGE formation can be studied in the laboratory by incubating reducing sugars, such as ribose or glucose with bovine serum albumin. AGE formation can be detected by increase in the fluorescence or increased cross reactivity with anti-AGE antibodies. The increase in fluorescence seems to precede formation of AGE specific antigenic epitopes. This increase in fluorescence is used to monitor the increased AGE formation in vitro (Brownlee M et al, Science 1986; 232:1629-1632). In addition to the increase in the fluorescence, one of the most important features of in vitro AGE formation is the formation of antigenic epitopes that are specific to AGE and not to the native proteins. Therefore, it is possible to raise antibodies against advanced glycation end products of one protein and use them to detect AGE formation in other proteins. This has served as an important analytical tool in AGE research.
Due to the clinical significance of AGE formation, many approaches are being used to diagnose, prevent, or revert AGE formation in the body. The formation of AGE could be inhibited by reacting with an early glycosylation product that results from the original reaction between the target protein and glucose. The inhibition was believed to take place as the reaction between the inhibitor and the early glycosylation product appeared to interrupt the subsequent reaction of the glycosylated protein with additional protein material to form the cross linked late stage product. Compounds like aminoguanidine act to inhibit AGE formation by such mechanism.
The formation of AGE on long-lived proteins is also associated with cross-linking of these proteins. The AGE derived protein cross-links have been shown to be cleaved by compounds like N- phenacyl thiazolium bromide (PTB), which reacts with and cleaves covalent, AGE derived protein cross links (Vasan et al. Nature 1996; 382: 275-278; U.S. Pat. No. 5,853,703, Date of Patent Dec.29, 1998). The mechanism of reducing the AGE content in tissues is expected to take place relatively rapidly, in contrast to aminoguanidine, which acts slowly by its very nature of mechanism of action. This current specification is related to compounds of pyridinium class, which break pre-formed AGE, like PTB, and in some cases even more effectively by than PTB.
SUMMARY OF THE INVENTION
The main objective of the present invention is to provide a new class of compounds of the pyridinium series which are useful for the management of diabetes and aging related vascular complications and particularly in the treatment of complications of diabetes mellitus and other aging related conditions including kidney disease, nerve damage, atherosclerosis, retinopathy and dermatological conditions. The invention also extends the method to reverse the discoloration of teeth resulting from nonenzymatic browning in the oral cavity which comprises administration of an amount effective to reverse the preformed advanced glycosylation crosslinks, etc.
Another object of the present invention is to provide compounds of the pyridinium series, which exhibit AGE breaking activities.
Yet another object of the present invention is to provide a method of preparation of compounds of the pyridinium series which exhibit AGE breaking activities.
Still another object of the invention is to provide pharmaceutical compositions with a new class of compounds of the pyridinium series according to the invention and their pharmaceutically acceptable salts in combination with suitable carriers, solvents, excepients, diluents and other media normally employed in preparing such compositions.
Still another object of the invention is to provide a method of treatment of a diabetic patient by administration of the compounds of the invention, either singly or in combination with drugs for anti-diabetic therapy, or pharmaceutically acceptable salts thereof in required dosage in admixture with pharmaceutically acceptable diluent, solvent, excepients, carriers or other media as may be appropriate for the purpose.
DETAILED DESCRIPTION OF THE INVENTION
The present invention provides for a new class of AGE breakers, of general formula I,
wherein
R
1
is —R
4
—R
5
or —N(R
7
)N(R
7
)R
9
;
R
4
is selected from the group consisting of —N(R
7
)R
6
O—, —N(R
7
)R
6
N(R
7
)—, OR
6
O, and —OR
6
N(R
7
)—, where R
6
is alkyl;
R
5
is selected from the group consisting of alkyl, aryl including heteroaryl, —COR
7
, SO
2
R
7
, —C(S)NHR
7
, —C(NH)NHR
7
, —COR
10
,
where
R
7
is selected from the group consisting of H, alkyl and aryl including heteroaryl provided R
7
might be different for R
1
and R
3
in the same compound; R
2
is selected from the group consisting of F, Cl, Br, I, OR
7
, NO
2
, alkyl, aryl including heteroaryl, formyl, acyl, C(O)NR
7
R
10
, C(O)OR
7
, NR
7
R
10
, N═C(R
7
)(R
10
), SR
7
, SO
2
NH
2
, SO
2
alkyl and SO
2
aryl, and m is 0, 1 or 2;
R
3
is selected from the group consisting of R
7
, OR
7
, N(R
7
)(R
10
), N═C(R
7
)(R
10
), N(R
7
)N(R
7
)(R
10
), N(R
7
)N═C(
7
)(R
10
) and CH(R
7
)C(O)R
8
where R
8
is selected from the group consisting of R
7
, OR
7
and NR
7
R
10
;
R
9
is selected from the group consisting of hydrogen, alkyl, aryl including heteroaryl, C(O)R
10
, —SO
2
R
10
, —C(S)NHR
10
, —C(NH)NH(R
10
) and —C(O)NHR
10
,
R
10
is selected for the group consisting of H, alkyl or aryl including heteroaryl and in each case optionally different from substituent R
10
, provided R
10
might be different for R
1
and R
3
in the same compound;
X is selected from group consisting of a halide ion,
Aulakh C. S.
Torrent Pharmaceuticals Ltd.
LandOfFree
Compounds for the management of aging-related and diabetic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds for the management of aging-related and diabetic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds for the management of aging-related and diabetic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2954163